Table: q1_q4_2022_prescription_drug_wac_increases , manufacturer_name like N*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id manufacturer_name date_reported ndc_number drug_product_description wac_effective_date wac_increase_amount wac_after_increase patent_expiration_date drug_source_type unit_sales_volume_in_us unit_sales_volume_non_public_indicator cost_increase_factors cost_increase_factors_non_public_indicator change_improvement_description change_improvement_non_public_indicator acquisition_date company_acquired_from acquisition_price acquisition_price_non_public_indicator acquisition_price_comment wac_at_acquisition wac_year_prior_to_acquisition year_drug_introduced_to_market wac_at_intro_to_market supporting_documents general_comments
Rx0000106 Neos Therapeutics, Inc. 12/31/2022 70165002030 ADZENYS XR-ODT 12.5MG, 30 CT Tablets 10/01/2022 21.78 457.38 06/28/2032 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000106 Neos Therapeutics, Inc. 12/31/2022 70165002530 ADZENYS XR-ODT 15.7MG, 30 CT Tablets 10/01/2022 21.78 457.38 06/28/2032 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000106 Neos Therapeutics, Inc. 12/31/2022 70165003030 ADZENYS XR-ODT 18.8MG, 30 CT Tablets 10/01/2022 21.78 457.38 06/28/2032 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000106 Neos Therapeutics, Inc. 12/31/2022 70165000530 ADZENYS XR-ODT 3.1MG, 30 CT Tablets 10/01/2022 21.78 457.38 06/28/2032 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000106 Neos Therapeutics, Inc. 12/31/2022 70165001030 ADZENYS XR-ODT 6.3MG, 30 CT Tablets 10/01/2022 21.78 457.38 06/28/2032 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000106 Neos Therapeutics, Inc. 12/31/2022 70165001530 ADZENYS XR-ODT 9.4MG, 30 CT Tablets 10/01/2022 21.78 457.38 06/28/2032 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000106 Neos Therapeutics, Inc. 12/31/2022 70165020030 COTEMPLA XR-ODT 17.3MG, 30 CT Tablets 10/01/2022 22.26 467.46 06/28/2032 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000106 Neos Therapeutics, Inc. 12/31/2022 70165030030 COTEMPLA XR-ODT 25.9MG, 30 CT Tablets 10/01/2022 22.26 467.46 06/28/2032 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000106 Neos Therapeutics, Inc. 12/31/2022 70165010030 COTEMPLA XR-ODT 8.6MG, 30 CT Tablets 10/01/2022 22.26 467.46 06/28/2032 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000366 Neurocrine Biosciences, Inc. 12/31/2022 70370204001 INGREZZA ORAL CAPSULE 40 MG, BOTTLE OF 30 CAPSULES 10/20/2022 603.00 7302.00 08/10/2040 Single Source Drug None 1 Patient access is a priority because discovering and developing new medicines alone is not enough. Important medical advancements can only change lives when they reach patients who need relief. We determine the price of our medicines based on their value and impact to patients, families, care partners, providers, payers, and society. In doing so, we adhere to the highest ethical and compliance standards and are guided by the following principles: -Improving the lives and well-being of patients -Maximizing access and reducing out-of-pocket costs for eligible patients -Striving to reduce obstacles for patients to fill a prescription or undergo treatment -Fueling the discovery and development of life-changing medicines None The price increase was not necessitated by a change or improvement in the prescription drug. None None None None None None None None None None None None
Rx0000366 Neurocrine Biosciences, Inc. 12/31/2022 70370108001 INGREZZA ORAL CAPSULE 80 MG, BOTTLE OF 30 CAPSULES 10/20/2022 662.00 8022.00 08/10/2040 Single Source Drug None 1 Patient access is a priority because discovering and developing new medicines alone is not enough. Important medical advancements can only change lives when they reach patients who need relief. We determine the price of our medicines based on their value and impact to patients, families, care partners, providers, payers, and society. In doing so, we adhere to the highest ethical and compliance standards and are guided by the following principles: -Improving the lives and well-being of patients -Maximizing access and reducing out-of-pocket costs for eligible patients -Striving to reduce obstacles for patients to fill a prescription or undergo treatment -Fueling the discovery and development of life-changing medicines None The price increase was not necessitated by a change or improvement in the prescription drug. None None None None None None None None None None None None
Rx0000366 Neurocrine Biosciences, Inc. 12/31/2022 70370204806 INGREZZA ORAL CAPSULE INITIATION PACK 40 MG (7) AND 80 MG (21), BLISTER PACK OF 28 CAPSULES 10/20/2022 662.00 8022.00 08/10/2040 Single Source Drug None 1 Patient access is a priority because discovering and developing new medicines alone is not enough. Important medical advancements can only change lives when they reach patients who need relief. We determine the price of our medicines based on their value and impact to patients, families, care partners, providers, payers, and society. In doing so, we adhere to the highest ethical and compliance standards and are guided by the following principles: -Improving the lives and well-being of patients -Maximizing access and reducing out-of-pocket costs for eligible patients -Striving to reduce obstacles for patients to fill a prescription or undergo treatment -Fueling the discovery and development of life-changing medicines None The price increase was not necessitated by a change or improvement in the prescription drug. None None None None None None None None None None None None
Rx0000364 NextWave Pharmaceuticals, Inc. 03/31/2022 24478032102 QUILLIVANT XR 300mg in 60mL Powder 1 60mL Bottle 1 Carton 01/03/2022 9.98 338.93 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000364 NextWave Pharmaceuticals, Inc. 03/31/2022 24478032204 QUILLIVANT XR 600mg in 120mL Powder 1 120mL Bottle 1 Carton 01/03/2022 9.98 338.93 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000364 NextWave Pharmaceuticals, Inc. 03/31/2022 24478032305 QUILLIVANT XR 900mg in 180mL Powder 1 180mL Bottle 1 Carton 01/03/2022 9.98 338.93 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000364 NextWave Pharmaceuticals, Inc. 03/31/2022 24478032406 QUILLIVANT XR750mg in 150mL Powder 1 150mL Bottle 1 Carton 01/03/2022 9.98 338.93 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000418 Nexus Pharmaceuticals, Inc. 09/30/2022 14789090110 Procainamide HCL 100 mg 10mL Vial Pack of 10 09/07/2022 3000.00 6000.00 None Non-innovator Multiple Source Drug 6790 None Nexus considers multiple factors in determining ongoing pricing of their prescription drugs including value provided to patients, patient populations and changing market and competitive conditions. None no change None None None None None None None None None None None None
Rx0000418 Nexus Pharmaceuticals, Inc. 09/30/2022 14789090002 Procainamide HCL 500mg 2mL Vial Pack of 10 09/07/2022 3000.00 6000.00 None Non-innovator Multiple Source Drug 15140 None Nexus considers multiple factors in determining ongoing pricing of their prescription drugs including value provided to patients, patient populations and changing market and competitive conditions. None no change None None None None None None None None None None None None
Rx0000420 Nielsen BioSciences, Inc. 12/31/2022 59584013801 Candin skin test antigen 1 U/.1mL 1mL vial liquid 10/10/2022 29.00 272.00 None Single Source Drug 31873 None When pricing its products, Nielsen takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. None None None None None None None None None None None None None None
Rx0000420 Nielsen BioSciences, Inc. 12/31/2022 59584014001 Spherusol skin test antigen 12.7 ug/mL 1mL vial liquid 10/10/2022 138.00 1056.00 None Single Source Drug 1155 None When pricing its products, Nielsen takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. None None None None None None None None None None None None None None
Rx0000204 Noden Pharma USA, Inc. 03/31/2022 70839015030 TEKTURNA 150MG TAB 30/EA 01/01/2022 22.02 266.64 08/19/2026 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000204 Noden Pharma USA, Inc. 03/31/2022 70839030030 TEKTURNA 300MG TAB 30/EA 01/01/2022 27.78 336.39 08/19/2026 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000204 Noden Pharma USA, Inc. 03/31/2022 70839031230 TEKTURNA HCT 300/12.5MG TAB 30/EA 01/01/2022 27.78 336.39 07/13/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000204 Noden Pharma USA, Inc. 03/31/2022 70839032530 TEKTURNA HCT 300/25MG TAB 30/EA 01/01/2022 27.78 336.39 07/13/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000073 Novartis 09/30/2022 00065027510 AZOPT® 1% 10 mL DT 07/27/2022 17.16 360.39 07/02/2017 Innovator Multiple Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Product was on the market at the time of the acquisition. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073 Novartis 09/30/2022 00065027515 AZOPT® 1% 15 mL DT 07/27/2022 25.74 540.54 07/02/2017 Innovator Multiple Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Product was on the market at the time of the acquisition. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073 Novartis 03/31/2022 00078063968 Cosentyx 150mg/ml, pen, 1 Sensoready Pen 01/05/2022 415.05 6344.38 05/05/2033 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 09/30/2022 00078063968 Cosentyx 150mg/ml, pen, 1 Sensoready Pen 07/27/2022 126.89 6471.27 05/05/2033 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2022 00078063941 Cosentyx 150mg/ml, pen, 2 Sensoready Pens 01/05/2022 415.05 6344.38 05/05/2033 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 09/30/2022 00078063941 Cosentyx 150mg/ml, pen, 2 Sensoready Pens 07/27/2022 126.89 6471.27 05/05/2033 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2022 00078063997 Cosentyx 150mg/ml, syringe, 1 Syringe 01/05/2022 415.05 6344.38 05/05/2033 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 09/30/2022 00078063997 Cosentyx 150mg/ml, syringe, 1 Syringe 07/27/2022 126.89 6471.27 05/05/2033 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2022 00078063998 Cosentyx 150mg/ml, syringe, 2 Syringes 01/05/2022 415.05 6344.38 05/05/2033 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 09/30/2022 00078063998 Cosentyx 150mg/ml, syringe, 2 Syringes 07/27/2022 126.89 6471.27 05/05/2033 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 09/30/2022 00065924007 DUREZOL® 0.05% 5 mL DT 07/27/2022 10.38 218.00 11/18/2019 Innovator Multiple Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073 Novartis 03/31/2022 00078065967 Entresto 24/26mg - Tabs, 180 Each Bottle, 1 bottle 01/05/2022 122.41 1871.09 05/09/2036 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 09/30/2022 00078065967 Entresto 24/26mg - Tabs, 180 Each Bottle, 1 bottle 07/27/2022 37.42 1908.51 05/09/2036 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2022 00078065920 Entresto 24/26mg - Tabs, 60 Each Bottle, 1 bottle 01/05/2022 40.80 623.69 05/09/2036 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 09/30/2022 00078065920 Entresto 24/26mg - Tabs, 60 Each Bottle, 1 bottle 07/27/2022 12.47 636.16 05/09/2036 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2022 00078077767 Entresto 49/51mg - Tabs, 180 Each Bottle, 1 bottle 01/05/2022 122.41 1871.09 05/09/2036 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 09/30/2022 00078077767 Entresto 49/51mg - Tabs, 180 Each Bottle, 1 bottle 07/27/2022 37.42 1908.51 05/09/2036 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2022 00078077720 Entresto 49/51mg - Tabs, 60 Each Bottle, 1 bottle 01/05/2022 40.80 623.69 08/22/2033 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2022 00078069667 Entresto 97/103mg - Tabs, 180 Each Bottle, 1 bottle 01/05/2022 122.41 1871.09 05/09/2036 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 09/30/2022 00078069667 Entresto 97/103mg - Tabs, 180 Each Bottle, 1 bottle 07/27/2022 37.42 1908.51 05/09/2036 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2022 00078069620 Entresto 97/103mg - Tabs, 60 Each Bottle, 1 bottle 01/05/2022 40.80 623.69 08/22/2033 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 09/30/2022 00078077720 ENTRESTO® tablets 49mg/51mg 60s 07/27/2022 12.47 636.16 05/09/2036 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 09/30/2022 00078069620 ENTRESTO® tablets 97mg/103mg 60s 07/27/2022 12.47 636.16 05/09/2036 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2022 00078060715 GILENYA capsules 0.5mg 30s 01/05/2022 454.77 9550.11 12/25/2027 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 09/30/2022 00078060715 GILENYA capsules 0.5mg 30s 07/27/2022 191.00 9741.11 12/25/2027 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 09/30/2022 00078074303 ILEVRO® 0.3% 3 mL 07/27/2022 6.46 329.47 03/31/2032 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073 Novartis 03/31/2022 00078086001 KISQALI 200mg daily dose, 1 blister pack x 21 tablets (21 tablets per carton) 01/05/2022 396.77 6064.92 04/14/2036 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2022 00078086742 KISQALI 400mg daily dose, 3 blister packs x 14 tablets (42 tablets per carton) 01/05/2022 793.54 12129.88 04/14/2036 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2022 00078087463 KISQALI 600mg daily dose, 3 blister packs x 21 tablets (63 tablets per carton) 01/05/2022 991.93 15162.35 04/14/2036 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2022 00078090961 KISQALI FEMARA CO-PACK, Kisqali 1 blister pack, containing 21 tablets 200mg per tablet, Femara 2.5mg 28s 01/05/2022 396.77 6064.92 04/14/2036 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2022 00078091661 KISQALI FEMARA CO-PACK, Kisqali 3 blister packs, containing 14 tablets (200mg per tablet) (400mg daily 01/05/2022 793.54 12129.88 04/14/2036 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2022 00078092361 KISQALI FEMARA CO-PACK, Kisqali 3 blister packs, containing 21 tablets (200mg per tablet) (600mg daily dose), Femara 2.5mg 28s 01/05/2022 991.93 15162.35 04/14/2036 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2022 00078097950 MAYZENT tablets .25mg 28s 01/05/2022 94.01 1974.15 11/30/2030 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 09/30/2022 00078097950 MAYZENT tablets .25mg 28s 07/27/2022 39.48 2013.63 11/30/2030 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2022 00078098615 MAYZENT tablets 2mg 30s 01/05/2022 402.89 8460.63 11/30/2030 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 09/30/2022 00078098615 MAYZENT tablets 2mg 30s 07/27/2022 169.21 8629.84 11/30/2030 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2022 00078066615 Mekinist 0.5 mg 30 tabs per bottle, 1 bottle 01/05/2022 203.63 3905.92 08/30/2033 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073 Novartis 09/30/2022 00078066615 Mekinist 0.5 mg 30 tabs per bottle, 1 bottle 07/27/2022 78.12 3984.04 08/30/2033 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073 Novartis 03/31/2022 00078066815 Mekinist 2 mg 30 tabs per bottle, 1 bottle 01/05/2022 693.04 13293.83 08/30/2033 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073 Novartis 09/30/2022 00078066815 Mekinist 2 mg 30 tabs per bottle, 1 bottle 07/27/2022 265.88 13559.71 08/30/2033 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073 Novartis 03/31/2022 00078070184 PIQRAY tablets 200mg 28s 01/05/2022 1224.80 18721.98 09/28/2030 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2022 00078071502 PIQRAY tablets 250mg 56s 01/05/2022 1224.80 18721.98 09/28/2030 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2022 00078070802 PIQRAY tablets 300mg 56s 01/05/2022 1224.80 18721.98 09/28/2030 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2022 00078068415 Promacta 12.5 mg, 30 tabs per bottle, 1 bottle 01/05/2022 394.82 6035.13 02/01/2028 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073 Novartis 09/30/2022 00078068415 Promacta 12.5 mg, 30 tabs per bottle, 1 bottle 07/27/2022 120.70 6155.83 02/01/2028 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073 Novartis 03/31/2022 00078068515 Promacta 25 mg, 30 tabs per bottle, 1 bottle 01/05/2022 394.82 6035.13 02/01/2028 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073 Novartis 09/30/2022 00078068515 Promacta 25 mg, 30 tabs per bottle, 1 bottle 07/27/2022 120.70 6155.83 02/01/2028 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073 Novartis 03/31/2022 00078068615 Promacta 50 mg, 30 tabs per bottle, 1 bottle 01/05/2022 714.50 10921.67 02/01/2028 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073 Novartis 09/30/2022 00078068615 Promacta 50 mg, 30 tabs per bottle, 1 bottle 07/27/2022 218.43 11140.10 02/01/2028 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073 Novartis 03/31/2022 00078068715 Promacta 75 mg, 30 tabs per bottle, 1 bottle 01/05/2022 1071.75 16382.51 02/01/2028 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073 Novartis 09/30/2022 00078068715 Promacta 75 mg, 30 tabs per bottle, 1 bottle 07/27/2022 327.65 16710.16 02/01/2028 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073 Novartis 03/31/2022 00078097261 PROMACTA powder for oral suspension 12.5mg 30s Kit 01/05/2022 394.82 6035.13 02/01/2028 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073 Novartis 09/30/2022 00078097261 PROMACTA powder for oral suspension 12.5mg 30s Kit 07/27/2022 120.70 6155.83 02/01/2028 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073 Novartis 09/30/2022 00078069761 PROMACTA® powder for oral suspension 12.5mg 30s Kit 07/27/2022 120.71 6156.16 02/01/2028 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073 Novartis 09/30/2022 00078068655 PROMACTA® tablets 50mg 14s 07/27/2022 101.94 5198.71 02/01/2028 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073 Novartis 03/31/2022 00078069819 Rydapt 25 mg, 112 tabs per bottle, 1 bottle 01/05/2022 1040.78 19964.05 12/02/2030 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None NDC 00078-0698-02 and 00078-0698-51 are not commercially available. The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2022 00078069899 Rydapt 25 mg, 56 tabs per bottle, 1 bottle 01/05/2022 520.39 9982.03 12/02/2030 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None NDC 00078-0698-02 and 00078-0698-51 are not commercially available. The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2022 00078068266 Tafinlar 50 mg, 120 tabs per bottle, 1 bottle 01/05/2022 495.30 9500.83 08/30/2033 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073 Novartis 09/30/2022 00078068266 Tafinlar 50 mg, 120 tabs per bottle, 1 bottle 07/27/2022 190.02 9690.85 08/30/2033 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073 Novartis 03/31/2022 00078068166 Tafinlar 75 mg, 120 tabs per bottle, 1 bottle 01/05/2022 638.32 12244.20 08/30/2033 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073 Novartis 09/30/2022 00078068166 Tafinlar 75 mg, 120 tabs per bottle, 1 bottle 07/27/2022 244.88 12489.08 08/30/2033 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073 Novartis 03/31/2022 00078059287 Tasigna 150mg, 28 capsule per bottle, 4 bottles 01/05/2022 944.77 16690.91 10/07/2032 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 09/30/2022 00078059287 Tasigna 150mg, 28 capsule per bottle, 4 bottles 07/27/2022 333.82 17024.73 10/07/2032 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2022 00078052687 Tasigna 200mg, 28 capsule per bottle, 4 bottles 01/05/2022 944.77 16690.91 10/07/2032 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 09/30/2022 00078052687 Tasigna 200mg, 28 capsule per bottle, 4 bottles 07/27/2022 333.82 17024.73 10/07/2032 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2022 00078095166 Tasigna 50mg, 120 capsule per bottle, 1 bottle 01/05/2022 1012.25 17883.06 10/07/2032 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 09/30/2022 00078095166 Tasigna 50mg, 120 capsule per bottle, 1 bottle 07/27/2022 357.66 18240.72 10/07/2032 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2022 00078067066 Votrient 200 mg 120 tabs per bottle, 1 bottle 01/05/2022 800.62 15357.34 10/19/2023 Single Source Drug None 1 Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000017 Noven Therapeutics, LLC 03/31/2022 68968051408 CombiPatch Transdermal Patch Twice Weekly 0.05-0.14 MG/DAY - 8 each 01/01/2022 11.02 231.49 None Single Source Drug None 1 The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None None None None None None None None None None None None
Rx0000017 Noven Therapeutics, LLC 03/31/2022 68968052508 CombiPatch Transdermal Patch Twice Weekly 0.05-0.25 MG/DAY - 8 each 01/01/2022 11.02 231.49 None Single Source Drug None 1 The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None None None None None None None None None None None None
Rx0000017 Noven Therapeutics, LLC 03/31/2022 68968555203 Daytrana Transdermal Patch 10 MG/9HR - 30 each 01/01/2022 20.99 440.97 10/07/2025 Single Source Drug None 1 The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None None None None None None None None None None None None
Rx0000017 Noven Therapeutics, LLC 03/31/2022 68968555303 Daytrana Transdermal Patch 15 MG/9HR - 30 each 01/01/2022 20.99 440.97 10/07/2025 Single Source Drug None 1 The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None None None None None None None None None None None None
Rx0000017 Noven Therapeutics, LLC 03/31/2022 68968555403 Daytrana Transdermal Patch 20 MG/9HR - 30 each 01/01/2022 20.99 440.97 10/07/2025 Single Source Drug None 1 The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None None None None None None None None None None None None
Rx0000017 Noven Therapeutics, LLC 03/31/2022 68968555503 Daytrana Transdermal Patch 30 MG/9HR - 30 each 01/01/2022 20.99 440.97 10/07/2025 Single Source Drug None 1 The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None None None None None None None None None None None None
Rx0000017 Noven Therapeutics, LLC 03/31/2022 68968662508 Minivelle Transdermal Patch Twice Weekly 0.025 MG/24HR - 8 each 01/01/2022 10.43 219.13 07/04/2030 Innovator Multiple Source Drug None 1 The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None None None None None None None None None None None None
Rx0000017 Noven Therapeutics, LLC 03/31/2022 68968663708 Minivelle Transdermal Patch Twice Weekly 0.0375 MG/24HR - 8 each 01/01/2022 10.43 219.13 07/04/2030 Innovator Multiple Source Drug None 1 The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None None None None None None None None None None None None
Rx0000017 Noven Therapeutics, LLC 03/31/2022 68968665008 Minivelle Transdermal Patch Twice Weekly 0.05 MG/24HR - 8 each 01/01/2022 10.43 219.13 07/04/2030 Innovator Multiple Source Drug None 1 The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None None None None None None None None None None None None
Rx0000017 Noven Therapeutics, LLC 03/31/2022 68968667508 Minivelle Transdermal Patch Twice Weekly 0.075 MG/24HR - 8 each 01/01/2022 10.43 219.13 07/04/2030 Innovator Multiple Source Drug None 1 The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None None None None None None None None None None None None
Rx0000017 Noven Therapeutics, LLC 03/31/2022 68968661008 Minivelle Transdermal Patch Twice Weekly 0.1 MG/24HR - 8 each 01/01/2022 10.43 219.13 07/04/2030 Innovator Multiple Source Drug None 1 The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None None None None None None None None None None None None
Rx0000033 Novo 03/31/2022 00169770521 Norditropin® FlexPro® 10mg/1.5mL 01/06/2022 66.66 1465.40 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Norditropin is no longer under patent. NNI is the original manufacturer of Norditropin and did not acquire the product from a different company.
Rx0000033 Novo 03/31/2022 00169770821 Norditropin® FlexPro® 15mg/1.5mL 01/06/2022 100.00 2198.10 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Norditropin is no longer under patent. NNI is the original manufacturer of Norditropin and did not acquire the product from a different company.
Rx0000033 Novo 03/31/2022 00169770321 Norditropin® FlexPro® 30mg/3.0mL 01/06/2022 199.99 4396.20 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Norditropin is no longer under patent. NNI is the original manufacturer of Norditropin and did not acquire the product from a different company.
Rx0000033 Novo 03/31/2022 00169770421 Norditropin® FlexPro® 5mg/1.5mL 01/06/2022 33.33 732.70 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Norditropin is no longer under patent. NNI is the original manufacturer of Norditropin and did not acquire the product from a different company.